Dock8 Antibody

What is DOCK8 and what is its role in immune function?

DOCK8 is a large 231 kDa protein composed of 2031 amino acids that functions as a regulator of the actin cytoskeleton with particular importance in immune cells . It plays a crucial role in both innate and adaptive immune responses. The DOCK8 gene is located on chromosome 9 and is expressed approximately ten times more abundantly in B and T lymphocytes than in other tissues . DOCK8 is essential for organizing B cell immunological synapses, similar to defects in B cell pSMAC (peripheral supramolecular activation cluster) formation caused by mutations in Rac2 or Rac GEFs Vav1/Vav2 . At the molecular level, DOCK8 functions in antigen recognition, being essential for recruiting ICAM-1 to the immunological synapse while being unnecessary for central events in BCR signaling to soluble ligands .

What are the common applications for DOCK8 antibodies in research?

DOCK8 antibodies are utilized across multiple experimental techniques including:

When selecting an antibody, researchers should consider the specific application and sample type, as reactivity has been confirmed in human, mouse, and rat samples . For DOCK8 deficiency testing in clinical settings, flow cytometry antibodies are used to evaluate DOCK8 expression on T cells (CD45+CD14[neg]CD3+), B cells (CD45+CD14[neg]CD3[neg]CD19+), and natural killer cells .

How do researchers validate DOCK8 antibody specificity in their experimental systems?

Validating DOCK8 antibody specificity requires a multi-faceted approach:

• Molecular weight verification: Confirm the antibody detects a protein of 230-239 kDa (observed molecular weight range) .

• Positive controls: Include cell lines with known DOCK8 expression such as Raji cells, THP-1 cells, or tissue samples like rat lung tissue that have been verified to express DOCK8 .

• Negative controls: Use DOCK8-deficient samples when available, or alternatively, primary isotype controls.

• KD/KO validation: Multiple publications have used knockdown or knockout systems to validate antibody specificity . This represents the gold standard for antibody validation.

• Multiple detection methods: Cross-validate findings using different techniques (e.g., if using WB for main experiments, confirm with IF or IHC).

How is DOCK8 deficiency diagnosed in a laboratory setting?

DOCK8 deficiency diagnosis typically employs a flow cytometry-based protein expression assay performed on whole blood. The methodology involves:

• Fixing and permeabilizing samples

• Staining with antibodies specific for CD45, CD14, CD19, CD3, and CD56

• Adding either DOCK8 antibody or isotype control (both unconjugated)

• Applying a secondary mouse anti-rabbit reporter antibody to assess DOCK8 and isotype control expression

• Analyzing samples on a flow cytometer

DOCK8 expression is evaluated on specific lymphocyte populations including T cells, B cells, and natural killer cells. This test is specifically designed for aiding in the diagnosis of DOCK8 deficiency but is not useful for assessing DOCK8 carrier status .

What is the mutational spectrum observed in DOCK8 deficiency and how does this impact antibody selection?

The majority of mutations causing DOCK8 deficiency are insertions and deletions, with some nonsense and splice junction point mutations. Notably, missense mutations are extremely rare, with only two having been described (p.C1447R and p.V797M) . This mutation spectrum is quite different from that of STAT3 deficiency, which is characterized by dominant-negative point mutations .

The nature of these mutations has important implications for antibody selection:

• Large deletions may completely eliminate epitopes, requiring antibodies targeting multiple regions of DOCK8

• Some mutations affect splicing, potentially creating truncated proteins that might still be detected with N-terminal targeting antibodies

• Preferentially select antibodies that target conserved regions unlikely to be affected by common DOCK8 mutations

For definitive diagnosis, clinicians may need to collect samples for both protein detection (via flow cytometry or immunoblotting) and mRNA analysis .

How can researchers optimize DOCK8 antibody protocols for studying B cell immune synapse formation?

Studying DOCK8's role in B cell immune synapse formation requires specialized experimental approaches:

• Sample preparation: Use primary B cells isolated from peripheral blood or splenic tissue, or B cell lines with verified DOCK8 expression.

• Antibody selection: Choose antibodies that specifically recognize functional domains of DOCK8 involved in immune synapse formation, particularly the DHR2 domain which is critical for GEF activity .

• Synaptic engagement: Create in vitro systems that model B cell immunological synapse formation using supported lipid bilayers containing anti-BCR antibodies and ICAM-1.

• Imaging optimization: Employ high-resolution microscopy techniques (confocal, TIRF, or super-resolution) with optimized antibody dilutions (typically starting with 1:100 for IF applications and adjusting as needed).

• Dual staining approach: Combine DOCK8 antibody staining with markers of immune synapse components (LFA-1, ICAM-1, BCR, actin).

Research by Randall et al. has demonstrated that DOCK8 plays a critical role in recruiting ICAM-1 to the immunological synapse but is unnecessary for central BCR signaling to soluble ligands leading to activation and proliferation . This indicates that experiments should focus on membrane dynamics rather than just signaling cascades.

What are the key methodological considerations when investigating DOCK8's role in germinal center B cell responses?

When studying DOCK8's function in germinal center (GC) B cell responses, consider these methodological approaches:

• Model system selection:

  • In vivo: Use DOCK8 mutant mouse models (cpm or pri mutations) for whole-organism studies

  • Ex vivo: Isolate and manipulate GC B cells from immunized animals

  • In vitro: Culture systems that model aspects of GC responses

• Experimental design for affinity maturation studies:

  • Immunize with defined antigens (e.g., HEL or SRBC) to track specific B cell responses

  • Use flow cytometry to isolate and analyze antigen-specific GC B cells

  • Sequence Igh genes from individual flow-sorted GC B cells to analyze somatic hypermutation patterns

  • Flow cytometric staining with defined antigen concentrations to enumerate high-affinity variants

• Analysis parameters:

  • Quantify GC B cell survival over time

  • Measure the ratio of replacement to silent mutations, particularly in CDR regions

  • Calculate the percentage of cells with specific advantageous mutations (like Y58F replacements in CDR2)

  • Determine the frequency of high-affinity IgG+ variants as a percentage of total B cells

Research has shown that DOCK8 deficiency allows normal immunoglobulin gene hypermutation but diminishes survival and selection, reducing the formation of higher affinity IgG+ B cells by approximately 200-fold .

How do you interpret conflicting data from DOCK8 antibody staining between different detection methods?

When faced with conflicting results between different detection methods:

• Epitope accessibility analysis: Different fixation and permeabilization protocols may affect epitope accessibility. For IHC applications, compare antigen retrieval with TE buffer pH 9.0 versus citrate buffer pH 6.0 .

• Protein conformation considerations: Native versus denatured conditions may influence antibody recognition. Western blot detects denatured protein, while IF and flow cytometry typically detect protein in more native conformations.

• Expression level analysis: Quantify relative expression levels across different tissues/cells. DOCK8 is expressed ten times more abundantly in lymphocytes than other tissues, which may explain detection discrepancies .

• Isoform detection: Verify which isoforms your antibody detects. The full-length DOCK8 protein (2031 aa, 231 kDa) may show slightly different observed molecular weights (230-239 kDa) on Western blots .

• Cross-reactivity assessment: Test for potential cross-reactivity with other DOCK family members, particularly those with homologous DHR2 domains (DOCK6, 7, and 9) .

What control samples should be included when investigating DOCK8 expression in immune deficiency research?

Robust experimental design requires appropriate controls:

For diagnostic applications, implementing a scoring system that distinguishes DOCK8 deficiency from other conditions with similar presentations (like STAT3 deficiency) is valuable. Research has shown that five clinical features (lung abnormalities, eosinophilia, upper respiratory infections, retained primary teeth, and fractures with minimal trauma) can distinguish DOCK8-deficient patients from STAT3-deficient patients with 91.4% sensitivity and 87.5% specificity .

How can DOCK8 antibodies be utilized to study its role in B cell-T cell interactions in germinal centers?

Recent research has revealed that B cell–intrinsic DOCK8 bolsters the ability of antigen-specific B cells to receive and integrate survival signals from T follicular helper cells in the germinal center, particularly when antigen is limiting . This finding opens new research avenues that can be explored using DOCK8 antibodies:

• Co-localization studies: Use multi-color immunofluorescence to investigate DOCK8 localization during B cell-T cell interactions at the immune synapse.

• Signaling pathway analysis: Combine DOCK8 antibodies with phospho-specific antibodies to map how DOCK8 influences downstream signaling pathways following B cell-T cell engagement.

• Temporal dynamics: Employ time-course experiments with DOCK8 antibodies to track protein expression and localization changes during different phases of germinal center reactions.

• Mutational analysis: Use antibodies that recognize specific domains to determine how mutations affect DOCK8's ability to mediate B cell-T cell interactions.

Understanding these interactions provides insights into how selection and affinity maturation of antigen-specific B cells can occur even when antigen levels in the germinal center are low .

What methodological approaches are recommended for comparing DOCK8 antibody responses in vaccination studies?

Vaccination studies involving DOCK8 antibody responses require careful methodological consideration:

• Quantification approaches: Use ELISA data with non-linear regression (curve fit) and EC50 shift analysis to allow comparison of antibody titration curves, particularly when evaluating the longevity of responses .

• Affinity assessment: Implement techniques to measure antibody affinity maturation, as DOCK8 deficiency specifically impairs the longevity and affinity maturation of T-dependent antibody responses while preserving T-independent antibody formation .

• Longitudinal sampling: Design studies with multiple time points (early, peak, and late) to capture the dynamics of antibody responses, as DOCK8 deficiency primarily affects the persistence of germinal center responses.

• Isotype analysis: Include comprehensive antibody isotype analysis, as class switching may be differentially affected.

Current published reports on vaccination responses in DOCK8 deficiency are contradictory, indicating the need for further investigation with standardized methodologies .